Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
Hepatocellular carcinoma · recurrent hepatocellular carcinoma · radiofrequency ablation · Stereotactic body radiotherapy · local progression-free survival · Progression-free survival · Overall survival · Local control rate · Small hepatocellular carcinoma · Randomized controlled trial · Ablation therapy · radiation therapy · hazard ratio · Adverse events · Tumor recurrence · single lesion · Locoregional therapy · Efficacy · Safety · open-label trial · acute adverse events · Long-term adverse events · 2-year local progression-free survival rate · Small hepatocellular carcinoma · HCC ≤5 cm · follow-up · liver cancer treatment
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459